Dipyridamole Induced Ischemia and Biomarkers

• Sponsor: University of Pecs (Other)
• Overall Status: Completed
• CT.gov ID: NCT03688815
• Collaborator: (none)
• Enrollment: 50
• Location: 1
• Actual Duration (Months): 96
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

Analysis of certain biomarkers and transient myocardial perfusion deficit revealed by myocardial perfusion scintigraphy.

Condition or Disease	Intervention/Treatment	Phase
Ischemic Heart Disease; Ischemic Attack	Diagnostic Test: myocardial perfusion scintigraphy

Detailed Description

The prospectively enrolled patients were followed up to 5 years. Adverse major events (MI, stroke, death) suffered during follow-up were retrospectively analysed.

Study Design

• Study Type: Observational
• Actual Enrollment: 50 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Relationship Between the L-arginine Pathway Metabolites and Dipyridamole Stress Induced Transient Myocardial Ischaemia
• Actual Study Start Date: Jan 1, 2009
• Actual Primary Completion Date: Jan 1, 2010
• Actual Study Completion Date: Jan 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Patients with ischemic heart disease Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.	Diagnostic Test: myocardial perfusion scintigraphy; Myocardial perfusion scintigraphy as it is described in the international literature.

Outcome Measures

Primary Outcome Measures

1. Myocardial perfusion abnormality [5 year follow-up after MPS]

   Myocardial perfusion was quantified based on myocardial perfusion scintigraphy (MPS).

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria: 1. written informed consent. 2. clinical diagnosis of ischemic heart disease (IHD) -

Exclusion Criteria: 1. refused written informed consent. 2. lost data during follow-up

-

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Pecs	Pécs	Baranya	Hungary	7624

Sponsors and Collaborators

• University of Pecs

Investigators

• Principal Investigator: Tihamer Molnar, MD, University of Pecs

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Regulation of Coronary Blood Flow in Health and Ischemic Heart Disease

Publications

None provided.

• Responsible Party: Tihamér Molnár, Associate professor, University of Pecs
• ClinicalTrials.gov Identifier: NCT03688815
• Other Study ID Numbers: PTE3950
• First Posted: Sep 28, 2018
• Last Update Posted: Sep 28, 2018
• Last Verified: Sep 1, 2018

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Heart Diseases; Myocardial Ischemia; Coronary Artery Disease; Ischemia

Study Results

No Results Posted as of Sep 28, 2018